mRNA Expression in DLBCL Patients who are CD20 Dim With an Eye Towards More Thoughtful Design of R/R Trials, Possibly Incorporating BCMA Bite Therapy
March 12, 2025
Bruce Hough, Maher Albitar Clinical Lymphoma, Myeloma and Leukemia, Vol. 000, No.xxx, 1–3 © 2025 Published by Elsevier Inc. Keywords: CD19 dim, Diffuse large b-cell lymphoma, Relapsed/Refractory, Bispecific T-cell engagers, Third line Introduction Diffuse Large B-cell Lymphoma (DLBCL) is the most common non-Hodgkin’s lymphoma with an estimated 80,620 new case